What is it about?
We investigated the absorption, distribution, metabolism and excretion profile of 14 C-radiolabeled mizagliflozin, a novel selective sodium glucose co-transporter 1 inhibitor designed to act only in the intestine.
Featured Image
Why is it important?
The investigation of pharmacokinetics profiles in rats helps us understand the pharmacokinetic character of mizagliflozin and also speculate about the pharmacokinetic properties of mizagliflozin in humans.
Perspectives
The pharmacokinetic character of mizagliflozin matches the concept of non-absorbable SGLT1 inhibitor and these findings should be useful for the accurate prediction of mizagliflozin pharmacokinetics in clinical settings.
Dr Yoshikazu Abe
Nihon Yakugakukai
Read the Original
This page is a summary of: Absorption, disposition, metabolism and excretion of [14C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats, Xenobiotica, March 2018, Taylor & Francis,
DOI: 10.1080/00498254.2018.1449269.
You can read the full text:
Contributors
The following have contributed to this page
